ARMK heads into its May 5 earnings release with analysts firmly in the bulls' corner — but the stock's options market tells a quieter story than the Wall Street consensus suggests.
The analyst backdrop is unusually constructive. Every recent rating action has been a target raise. UBS lifted its target to $48 in early April. Oppenheimer moved to $50 in late March. Truist and Citigroup both raised to $50 and $51 respectively after the February print. The consensus mean target of $47.63 sits modestly above the current $44.95 close, implying limited but positive upside. The direction of travel is clear — the Street has been consistently upgrading its view of Aramark's earnings power. The EPS momentum factor scores underscore this: 12-month forward EPS growth ranks in the 94th percentile of the broader universe.
Options positioning does not reflect that enthusiasm. The put/call ratio is running at just 0.086 — well below its 20-day average of 0.113 and near the 52-week low of 0.052. That lopsided call-heavy skew points to a market where hedging demand is minimal and call speculation is more prevalent. The z-score of -0.57 confirms the read: options traders are not bracing for a downside shock. The last print reinforces the upside reflex — the stock jumped nearly 9% on the day after February's Q1 results, though the five-day follow-through faded to roughly 1%.
Short interest is a secondary consideration here. At 4.2% of free float, the position is modest. It dropped sharply in the week ending April 30, falling roughly 9% over seven days to around 10.9 million shares — reversing a mid-April spike that briefly pushed the float short above 4.6%. Borrowing conditions are extremely relaxed: the cost to borrow has collapsed by half over the past month to just 0.25%, and availability is vast. There is no meaningful short pressure built into this name.
The institutional register is stable and well-held. Capital Research, Vanguard, and BlackRock each own roughly 9% of shares and added marginally in Q1. AQR Capital added over 5 million shares as of the December quarter — the largest incremental change among major holders. Insider activity, by contrast, has been exclusively on the sell side over recent months, though all transactions were small and low-significance.
The May 5 print will test whether Aramark's contract pipeline and international growth can sustain the EPS trajectory that analysts have been chasing upward all year, and whether margins can hold in a still-uncertain labour cost environment.
See the live data behind this article on ORTEX.
Open ARMK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
